Pharmaceutical News

Archimedes Development Limited (ADL) is a subsidiary of Archimedes Pharma, a fast growing pharmaceutical company focused on meeting the needs of specialist prescribers in Europe. ADL is focused on partnering with companies which have compounds which could benefit from its suite of world-class drug delivery technologies. These comprise two cutting intra-nasal delivery technologies ChiSys^® and PecSys^TM as well TARGIT^®, which is designed to deliver drugs to precise regions of the large intestine. These technologies are able to optimise the profile of a wide range of drugs by allowing targeted or controlled release.

ADL’s world-class drug delivery technologies have been validated in a series of partnerships with pharmaceutical and biotechnology companies.  ADL has a flexible approach to its partnering activities and can apply its technologies to both existing and new therapeutic products.

ADL currently has development deals in place with a range of companies. Archimedes’ transmucosal enhancement technology ChiSys^® is being used by Javelin Pharmaceuticals for its nasally-delivered morphine product, Rylomine^TM* and PecSys^TM, a novel pectin-based nasal drug delivery technology designed to maximise the potential of systemically absorbed drugs by enhancing drug performance and improving patient acceptance is also being used in other development deals.
ADL also has a co-development and commercialisation agreement with Pharmalink AB under which the two parties are developing a TARGIT^® formulation for an anti-inflammatory product candidate. The TARGIT^® technology is also licensed to Invapharm for specific drug candidates for various indications.